CSL (OTCMKTS:CSLLY) Sets New 52-Week High – Still a Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price reached a new 52-week high during trading on Thursday. The stock traded as high as $36.88 and last traded at $36.88, with a volume of 5,472 shares. The stock had previously closed at $34.64.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Royal Bank Of Canada raised CSL from a “hold” rating to a “moderate buy” rating in a report on Tuesday, September 15th. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold”.

CSL Stock Down 0.6%

The firm’s 50-day simple moving average is $32.40 and its 200-day simple moving average is $29.73. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.97 and a current ratio of 2.21.

About CSL

CSL Limited is an Australian biotechnology company that develops and manufactures medicines and vaccines for people with serious and rare conditions. Its businesses include CSL Behring, which produces plasma-derived and recombinant therapies; CSL Seqirus, a developer of influenza vaccines and other related products; and CSL Vifor, which focuses on iron deficiency and kidney and related diseases.

CSL’s treatments address areas including bleeding disorders, immune deficiencies and respiratory conditions.